State-of-the-art automated 3D imaging workcell
The Organoid Innovation Center at Molecular Devices combines cutting-edge technologies with novel research methods to address key challenges of scaling complex 3D biological models.
El espacio de colaboración lleva a los clientes e investigadores al laboratorio para probar flujos de trabajo automatizados para el cultivo y cribado de organoides, con la orientación de científicos internos.
Más información
cultivo celular 3d
An automated, end-to-end integrated solution helps standardize the organoid development process with cell culture, treatment, and incubation, through to imaging, analysis, and AI data processing, delivering consistent, unbiased, and biologically-relevant results at scale.
Más información
Cell Engineering
The addition of our colony picker platform expands the Center’s state-of-the-art methods and technologies to include automated workflows for synthetic biology, antibody discovery, and cell line development.
And, with the recent launch of CloneSelect® Imager FL with multi-channel fluorescence for day zero monoclonality verification and confirmation of CRISPR edits, provides a wide range of cell and gene therapy applications.
Más información
Automatización de laboratorios
From our PhD-level technical support staff to our expert-trained and certified field service engineers, our Global Professional Services teams guide scientists through customized automation solutions that are uniquely designed to meet the specific needs of your assay, method, or protocol.
We offer a highly consultative approach when automating high-throughput plate-based, cellular screening, and clone screening assays with customized, automated labware, robotic solutions, and intuitive software.
Más información
Cardiac Organoids (Cardioid) for Drug Discovery
“The combination of HeartBeat.bio’s proprietary Cardioid technology and Molecular Devices’ automated 3D cell culture and image analysis solutions, defines a powerful and compelling partnership. Together, we are committed to develop and commercialize the world’s first integrated, end-to-end high-throughput human cardiac organoid screening platform.”
– Michael Krebs, CEO of HeartBeat.bio.
